Morgan Stanley
CDIO icon

Morgan Stanley’s Cardio Diagnostics CDIO Stock Holding History

Morgan Stanley’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$219 Hold
100
– – ﹤0.01% 7835
2026
Q1 		$195 Hold
100
– – ﹤0.01% 7698
2025
Q4 		$271 Sell
100
-23
-19% -$84 ﹤0.01% 7597
2025
Q3 		$493 Buy
123
+23
+23% +$91 ﹤0.01% 7497
2025
Q2 		$360 Sell
100
-50
-33% -$374 ﹤0.01% 7496
2025
Q1 		$1.49K Buy
150
+50
+50% +$779 ﹤0.01% 7232
2024
Q4 		$2.75K Buy
100
+67
+203% +$929 ﹤0.01% 7137
2024
Q3 		$223 Buy
+33
New +$405 ﹤0.01% 7376
2023
Q1 		– Hold
0
– -$3 – 7728
2022
Q4 		– Hold
0
– – – 7845

Other funds holding CDIO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley's CDIO Position: Q2 2026 in Review

Morgan Stanley held its Cardio Diagnostics (CDIO) position steady in Q2 2026 at 100 shares worth $219. The position accounts for ﹤0.01% of the portfolio, ranked #7835.

Morgan Stanley first reported a position in CDIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.75K in Q4 2024. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

  • Morgan Stanley held 100 shares of Cardio Diagnostics worth $219 as of Q2 2026.
  • Morgan Stanley left its Cardio Diagnostics share count unchanged in Q2 2026.
  • Cardio Diagnostics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7835 holding.
  • Morgan Stanley first reported a position in Cardio Diagnostics in Q3 2024 and has held it in 8 quarters since.
  • Morgan Stanley's Cardio Diagnostics position peaked at $2.75K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.